Why Integra LifeSciences (IART) stock is falling today
What happened?
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 7.3% in the afternoon session after the company reported third-quarter financial results featuring operational disruptions from plant flooding and projected a revenue contraction for the fourth quarter.
According to a company press release, Integra LifeSciences delivered third-quarter revenue of $411.2 million and adjusted diluted earnings per share of $0.59, as gains in Specialty Surgery were dampened by softer performance in Tissue Reconstruction. While revenue met Wall Street expectations and adjusted profit beat estimates by 5.5%, investors focused on forward-looking challenges. The release also said the company absorbed an estimated $7 million revenue hit due to flood damage and operational disruptions at its Cincinnati manufacturing facility.
For the fourth quarter, Integra forecast revenue between $413 million and $433 million, representing a contraction of 0.5% to 5.2%. At the midpoint of $423 million, the outlook came in below analyst estimates of $433.2 million. Additionally, the company expected its post-refinancing effective interest rate increase to track toward the upper end of a 100- to 200-basis-point range. The projected sales contraction and rising borrowing costs underscored persistent operational hurdles, weighing on investor sentiment.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.
What is the market telling us
Integra LifeSciences’s shares are very volatile and have had 25 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 19 days ago when the stock dropped 15.3% on the news that the company released preliminary third-quarter 2026 results and reduced its full-year revenue and adjusted EPS guidance due to operational disruption caused by a July 2026 flood at its Cincinnati facility. In a corporate update, Integra noted progress on business continuity efforts following the flooding incident. The company stated that it anticipates third-quarter operating cash flow to exceed $85 million, with full-year operating cash flow projected between $190 million and $200 million.
Integra LifeSciences is up 3.2% since the beginning of the year, but at $12.41 per share, it is still trading 37.5% below its 52-week high of $19.85 from July 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at only $174.76.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.